Glofitamab, sold under the brand name Columvi, is a bispecific monoclonal antibody used for the treatment of large B-cell lymphoma. It is a bispecific...
15 KB (1,046 words) - 20:02, 27 August 2024
Bi-specific T-cell engager (section Glofitamab)
Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct...
9 KB (1,472 words) - 21:30, 9 September 2024
(Bevacizumab) Leukemia/lymphoma lymphoid: CD3 (Glofitamab, Elranatamab, Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab...
12 KB (794 words) - 03:30, 2 September 2024
(Bevacizumab) Leukemia/lymphoma lymphoid: CD3 (Glofitamab, Elranatamab, Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab...
12 KB (758 words) - 23:46, 14 March 2024
adult patients with relapsed or refractory DLBCL after systemic therapy. Glofitamab (Columvi) is a bispecific monoclonal antibody that was approved for medical...
69 KB (8,143 words) - 18:36, 22 January 2024
carcinoma Glembatumumab vedotin mab human GPNMB melanoma, breast cancer Glofitamab Columvi BsAb humanized CD20, CD3 Y diffuse large B-cell lymphoma Golimumab...
136 KB (4,020 words) - 07:14, 15 August 2024
Mosunetuzumab L01FX26 Mirvetuximab soravtansine L01FX27 Epcoritamab L01FX28 Glofitamab L01FX29 Talquetamab L01FY01 Pertuzumab and trastuzumab L01FY02 Nivolumab...
12 KB (877 words) - 15:36, 25 January 2024
amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab. Among the bsAb programs currently under development, the combination...
29 KB (3,349 words) - 19:04, 30 July 2024
(INN) glisoxepide (INN) globin zinc insulin injection (INN) Glofil-125 glofitamab (INN) gloxazone (INN) gloximonam (INN) Glucagen glucagon (INN) glucalox...
14 KB (637 words) - 20:46, 27 August 2024
Etaracizumab§ Farletuzumab§ Ficlatuzumab§ Flotetuzumab§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab§ Inotuzumab ozogamicin Labetuzumab§ Lifastuzumab vedotin§...
3 KB (129 words) - 01:04, 19 July 2023
Etaracizumab§ Farletuzumab§ Ficlatuzumab§ Flotetuzumab§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab§ Inotuzumab ozogamicin Labetuzumab§ Lifastuzumab vedotin§...
5 KB (368 words) - 15:29, 21 August 2024
Etaracizumab§ Farletuzumab§ Ficlatuzumab§ Flotetuzumab§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab§ Inotuzumab ozogamicin Labetuzumab§ Lifastuzumab vedotin§...
4 KB (241 words) - 13:42, 14 July 2024